Manojkumar Bupathi, MD
Hematology & Oncology · Littleton, CONPI 1265675433
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.1%. Reporting peaked in 2019 at $61,800 and has fallen 50.7% since, to $30,438 in 2025. Among hematology & oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $896.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$47K
- Johnson & Johnson$37K
- AstraZeneca$28K
- E.r. Squibb & Sons, L.L.C.$27K
- Bayer$24K
- EMD Serono, Inc.$22K
- plus $127K from 29 others
Across 1,055 payments — averaging $7391.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1.4M
- Gilead$1.1M
- Seagen Inc.$1M
- AstraZeneca$959K
- Genentech, Inc.$758K
- Amgen$466K
- plus $2.1M from 16 others
What the payments were for
- Consulting fees$149,69348%
- Speaking & faculty fees$139,06645%
- Travel & lodging$16,4115%
- Food & beverage$5,9772%
- Education$9590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 53 | $47,026 |
| Johnson & Johnson | 42 | $37,016 |
| AstraZeneca | 19 | $27,774 |
| E.r. Squibb & Sons, L.L.C. | 33 | $27,320 |
| Bayer | 18 | $24,080 |
| EMD Serono, Inc. | 14 | $21,963 |
| Merck | 18 | $20,597 |
| Eisai Inc. | 18 | $19,652 |
| Pfizer | 20 | $16,270 |
| Sumitomo Pharma America, Inc. | 1 | $12,790 |
| Astellas Pharma US Inc | 18 | $10,388 |
| Seagen Inc. | 14 | $10,250 |
| Astellas Pharma Global Development | 9 | $6,434 |
| Gilead | 12 | $4,287 |
| Amgen | 5 | $3,555 |
| Genentech USA, Inc. | 7 | $3,378 |
| Novartis | 4 | $2,582 |
| Sanofi | 1 | $2,108 |
| AVEO Pharmaceuticals, Inc. | 8 | $2,040 |
| Immunomedics, Inc. | 1 | $2,025 |
| Progenics Pharmaceuticals, Inc. | 1 | $1,980 |
| Foundation Medicine, Inc. | 1 | $1,800 |
| Janssen Scientific Affairs, LLC | 2 | $1,575 |
| Regeneron Healthcare Solutions, Inc. | 3 | $1,546 |
| Daiichi Sankyo Inc. | 1 | $1,471 |
| Bristol Myers Squibb | 3 | $978 |
| Myovant Sciences Inc. | 4 | $832 |
| Tersera Therapeutics LLC | 5 | $144 |
| AbbVie | 5 | $101 |
| Iovance Biotherapeutics, Inc. | 2 | $41 |
| Tolmar, Inc. | 2 | $37 |
| Blue Earth Diagnostics | 1 | $23 |
| Pharmaand GmbH | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$312,106 in reported general payments places this provider in the 95th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 74 | $1,607,190 |
| ErleadaApalutamide | 98 | $1,234,071 |
| InlytaAxitinib | 41 | $744,423 |
| VerzenioAbemaciclib | 49 | $741,989 |
| XtandiEnzalutamide | 49 | $713,707 |
| LenvimaLenvatinib Mesylate | 29 | $699,475 |
| IbrancePalbociclib | 29 | $462,042 |
| NubeqaDarolutamide | 23 | $318,148 |
| OrgovyxRelugolix | 51 | $186,608 |
| EliquisApixaban | 119 | $98,997 |
| XareltoRivaroxaban | 52 | $42,005 |
| Abiraterone Acetate | 80 | $35,311 |
| Everolimus | 19 | $23,036 |
| Letrozole | 831 | $18,640 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $10,827 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $47,026 | $1,607,19074 claims |
| PfizerInlyta, Ibrance, Eliquis | $16,270 | $1,305,462189 claims |
| Johnson & JohnsonErleada, Xarelto | $37,016 | $1,276,076150 claims |
| Astellas Pharma US IncXtandi, Veozah | $10,388 | $722,25263 claims |
| Eisai Inc.Lenvima | $19,652 | $699,47529 claims |
| BayerNubeqa | $24,080 | $318,14823 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $12,790 | $186,60851 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,575 | $35,31180 claims |
| AbbVieSynthroid | $101 | $47711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Littleton
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- John BurkeAurora$321K
- Steven SchusterFort Collins$298K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Robert RifkinDenver$270K
- Christopher BentonEnglewood$249K
- Mabel MardonesDenver$149K
- Peter ForsbergDenver$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.